Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

Patients with migraine discontinued treatment less often with atogepant and experienced a greater reduction in mean monthly migraine days compared with topiramate, according to topline results from a ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential drug targets for the treatment of multiple sclerosis. The study may pave the ...

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.

(HealthDay News) — For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and Migraine Disability Assessment (MIDAS) scores, according ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

MR is associated with better treatment response than gepants in patients with migraine who previously had an inadequate response to gepants.

A 75% plus increase in good days/month with eptinezumab is associated with improved migraine symptoms, brain fog, and overall well-being in chronic migraine.